3/25
05:05 pm
asnd
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization [Yahoo! Finance]
Low
Report
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization [Yahoo! Finance]
3/20
09:28 pm
asnd
Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention [Yahoo! Finance]
Low
Report
Ascendis Pharma Trial Wins And Valuation Gap Draw Investor Attention [Yahoo! Finance]
3/17
09:05 am
asnd
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 [Yahoo! Finance]
Low
Report
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52 [Yahoo! Finance]
3/17
08:30 am
asnd
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
Low
Report
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52
3/16
10:58 am
asnd
Ascendis Pharma A/S (ASND) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Ascendis Pharma A/S (ASND) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
3/16
08:00 am
asnd
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
Low
Report
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026
3/12
08:48 am
asnd
Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy
Low
Report
Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy
3/5
05:03 pm
asnd
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by Bank of America Corporation.
Low
Report
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by Bank of America Corporation.
3/4
10:52 pm
asnd
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]
Low
Report
Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference [Yahoo! Finance]
3/4
10:14 pm
asnd
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia [Yahoo! Finance]
Low
Report
Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia [Yahoo! Finance]
3/4
09:09 pm
asnd
Ascendis Pharma A/S (ASND) was given a new $332.00 price target by Stifel Nicolaus.
Low
Report
Ascendis Pharma A/S (ASND) was given a new $332.00 price target by Stifel Nicolaus.
3/4
06:06 am
asnd
Ascendis Wins FDA Approval For Rare Disease Therapy [Yahoo! Finance]
Low
Report
Ascendis Wins FDA Approval For Rare Disease Therapy [Yahoo! Finance]
3/2
09:02 pm
asnd
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Low
Report
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
3/2
05:00 pm
asnd
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript [Seeking Alpha]
Low
Report
Ascendis Pharma A/S (ASND) Discusses FDA Approval and Commercial Launch Plans for YUVIWEL Transcript [Seeking Alpha]
3/2
04:22 pm
asnd
Ascendis wins FDA approval of dwarfism drug [Yahoo! Finance]
Low
Report
Ascendis wins FDA approval of dwarfism drug [Yahoo! Finance]
3/2
01:05 pm
asnd
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wolfe Research.
Low
Report
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Wolfe Research.
3/2
01:05 pm
asnd
Ascendis Pharma A/S (ASND) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Low
Report
Ascendis Pharma A/S (ASND) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
3/2
11:04 am
asnd
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Evercore Inc.
Medium
Report
Ascendis Pharma A/S (ASND) had its "outperform" rating reaffirmed by Evercore Inc.
3/2
08:43 am
asnd
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
Low
Report
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
3/2
07:01 am
asnd
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by The Goldman Sachs Group, Inc..
Medium
Report
Ascendis Pharma A/S (ASND) had its "buy" rating reaffirmed by The Goldman Sachs Group, Inc..
2/27
06:15 pm
asnd
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older [Yahoo! Finance]
Medium
Report
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older [Yahoo! Finance]
2/27
05:57 pm
asnd
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
Medium
Report
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
2/24
09:32 pm
asnd
Assessing Ascendis Pharma (ASND) Valuation After Strong 1 Year Return And Growing Growth Expectations [Yahoo! Finance]
Low
Report
Assessing Ascendis Pharma (ASND) Valuation After Strong 1 Year Return And Growing Growth Expectations [Yahoo! Finance]
2/23
05:31 pm
asnd
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
Low
Report
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
2/23
05:31 pm
asnd
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight
Low
Report
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight